NCT05937152View on ClinicalTrials.gov

A Study of CGRP Monoclonal Antibody to Treat Diabetic Neuropathy

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

January 31, 2025

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions
Diabetic Polyneuropathy
Interventions
DRUG

Eptinezumab

Intravenous (IV) infusion of 300 mg

DRUG

Placebo

Intravenous (IV) infusion of placebo (looks exactly like the study drug, but it contains no active ingredients)

Trial Locations (3)

55905

Mayo Clinic Minnesota, Rochester

Unknown

Steno Diabetes Center Aarhus, Aarhus

Steno Diabetes Center Copenhagen, Copenhagen

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT05937152 - A Study of CGRP Monoclonal Antibody to Treat Diabetic Neuropathy | Biotech Hunter | Biotech Hunter